A Phase 2, Open-label Multi-center Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Apremilast in Subjects With Recalcitrant Plaque-type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 10 Jun 2017 Biomarkers information updated
- 02 Sep 2009 Actual end date (May 2009) and actual number of patients (31) added as reported by ClinicalTrials.gov.
- 02 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.